期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

转移性肾细胞癌的靶向治疗

下载PDF
导出
摘要 肾细胞癌（renal cell carcinoma，RCC）约占成人恶性肿瘤的2％～3％，在男性泌尿生殖系统恶性肿瘤中发病率仅次于膀胱癌而居第2位.近年来，随着生活方式的改变及人口老龄化问题的出现，我国RCC的发病率有逐年上升的趋势。
作者 张鹏 王子明
机构地区 西安交通大学医学院第二附属医院泌尿外科
出处 《现代泌尿生殖肿瘤杂志》 2013年第1期57-60,共4页 Journal of Contemporary Urologic and Reproductive Oncology
关键词 转移性肾细胞癌 靶向治疗 生殖系统恶性肿瘤 CARCINOMA 人口老龄化 CELL 生活方式 发病率
分类号 R737.11 [医药卫生—肿瘤]
  • 相关文献

参考文献26

  • 1Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin,2010,60(5) :277-300.
  • 2Weikert S, Ljungberg B. Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention[J]. World J Urol,2010,28(3) :247-252.
  • 3Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and man- agement of recurrent disease[J]. Urol Clin North Am, 2003,30 (4) :843-852.
  • 4Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma[J]. N Engl J Med,1996,335(12) :865-875.
  • 5Kondok K, Yao M, Yoshida M, et al. Comprehensive muta- tional analysis of the VHL gene in sporadic renal cell carcino- ma: relationship to clinicopathological parameters[J]. Genes Chromosomes Cancer, 2002,34 (1) : 58-68.
  • 6Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome[J]. Nat Rev Cancer,2002,2(9):673-682.
  • 7Masson N, Willam C, Maxwell PH, et al. Independent func- tion of two destruction domains in hypoxia-inducible factor-al pha chains activated by prolyl hydroxylation[J]. EMBO J, 2001,20( 18): 5197-5206.
  • 8Cohen HT, MeGovern FJ. Renal cell carcinoma[J]. N Engl J Med, 2005,353(23) : 2477-2490.
  • 9KaelinWG Jr. The von Hippe-Lindau tumor suppressor gene and kidney cancer[J]. Clin Cancer Res,2004,10(18 Pt 2): 6290S-6295S.
  • 10Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma[J]. N Engl J Med,2007,356(2): 125-134.

二级参考文献42

  • 1陆嘉德,郭晔.肿瘤靶向治疗新探:多靶点Raf激酶抑制剂[J].中国癌症杂志,2007,17(1):1-7. 被引量：12
  • 2Lee JT, McCubrey JA. BAY-43-9006 Bayer/Onyx. Curr Opin Investig Drugs, 2003, 4: 757-763.
  • 3Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356:125-134.
  • 4Wilhelm SM, Carter C,Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004, 64: 7099-7109.
  • 5Awada A, Hendlisz A, Git T, et al. Safety and pharmacokinetics of BAY 43 9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer, 2005, 92: 1855-1861.
  • 6Ratain MJ, Eisen T, Stadler WM, et al. Phase Ⅱ placebo controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24; 2505-2512.
  • 7Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oneol, 2002, 20, 289-296.
  • 8Knox JJ, Figlin RA, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. J Clin Oneol, 2007, 25(Suppl) : 241.
  • 9Akaza H, Tsukamoto T, Murai M, et al. Phase Ⅱ study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. JpnJ Clin Oncol, 2007, 37: 755-762.
  • 10Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol, 2008, 158: 592-596.

共引文献73

现代泌尿生殖肿瘤杂志
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部